Literature DB >> 19240168

Palettes of vaccines and immunostimulatory monoclonal antibodies for combination.

Ignacio Melero1, Ivan Martinez-Forero, Juan Dubrot, Natalia Suarez, Asis Palazón, Lieping Chen.   

Abstract

Various monoclonal antibodies (mAb) target immune system molecules to enhance immunity by costimulating T cells (i.e., CD137, OX40, CD40, GITR) or interfering in coinhibitory signals (i.e., CTLA-4, PD-1). These powerful agents can be guided by cancer vaccines to enhance immunity against tumor but not self tissues. Clinically powerful therapeutic synergies are at hand.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19240168      PMCID： PMC3653776          DOI： 10.1158/1078-0432.CCR-08-2931

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  13 in total

Review 1.  The promise of cancer vaccines.

Authors:  Eli Gilboa
Journal:  Nat Rev Cancer       Date:  2004-05       Impact factor: 60.716

2.  OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.

Authors:  Satoshi Murata; Brian H Ladle; Peter S Kim; Eric R Lutz; Matthew E Wolpoe; Susan E Ivie; Holly M Smith; Todd D Armstrong; Leisha A Emens; Elizabeth M Jaffee; R Todd Reilly
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

Review 3.  Immunostimulatory monoclonal antibodies for cancer therapy.

Authors:  Ignacio Melero; Sandra Hervas-Stubbs; Martin Glennie; Drew M Pardoll; Lieping Chen
Journal:  Nat Rev Cancer       Date:  2007-02       Impact factor: 60.716

4.  B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells.

Authors:  Takeshi Azuma; Sheng Yao; Gefeng Zhu; Andrew S Flies; Sarah J Flies; Lieping Chen
Journal:  Blood       Date:  2008-01-25       Impact factor: 22.113

5.  Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.

Authors:  A van Elsas; A A Hurwitz; J P Allison
Journal:  J Exp Med       Date:  1999-08-02       Impact factor: 14.307

6.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.

Authors:  Cheryl L Day; Daniel E Kaufmann; Photini Kiepiela; Julia A Brown; Eshia S Moodley; Sharon Reddy; Elizabeth W Mackey; Joseph D Miller; Alasdair J Leslie; Chantal DePierres; Zenele Mncube; Jaikumar Duraiswamy; Baogong Zhu; Quentin Eichbaum; Marcus Altfeld; E John Wherry; Hoosen M Coovadia; Philip J R Goulder; Paul Klenerman; Rafi Ahmed; Gordon J Freeman; Bruce D Walker
Journal:  Nature       Date:  2006-08-20       Impact factor: 49.962

7.  Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.

Authors:  Fumiya Hirano; Katsumi Kaneko; Hideto Tamura; Haidong Dong; Shengdian Wang; Masao Ichikawa; Cecilia Rietz; Dallas B Flies; Julie S Lau; Gefeng Zhu; Koji Tamada; Lieping Chen
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

8.  Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.

Authors:  F Stephen Hodi; Marcus Butler; Darryl A Oble; Michael V Seiden; Frank G Haluska; Andrea Kruse; Suzanne Macrae; Marybeth Nelson; Christine Canning; Israel Lowy; Alan Korman; David Lautz; Sara Russell; Michael T Jaklitsch; Nikhil Ramaiya; Teresa C Chen; Donna Neuberg; James P Allison; Martin C Mihm; Glenn Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

9.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Authors:  G Dranoff; E Jaffee; A Lazenby; P Golumbek; H Levitsky; K Brose; V Jackson; H Hamada; D Pardoll; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

10.  Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.

Authors:  Betty Li; Jianmin Lin; Melinda Vanroey; Maria Jure-Kunkel; Karin Jooss
Journal:  Clin Immunol       Date:  2007-08-13       Impact factor: 3.969
View more
  13 in total

Review 1.  Emerging Opportunities and Challenges in Cancer Immunotherapy.

Authors:  Theresa L Whiteside; Sandra Demaria; Maria E Rodriguez-Ruiz; Hassane M Zarour; Ignacio Melero
Journal:  Clin Cancer Res       Date:  2016-04-15       Impact factor: 12.531

Review 2.  Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy.

Authors:  Dallas B Flies; Britt J Sandler; Mario Sznol; Lieping Chen
Journal:  Yale J Biol Med       Date:  2011-12

Review 3.  Experimental mouse tumour models: what can be learnt about human cancer immunology?

Authors:  Glenn Dranoff
Journal:  Nat Rev Immunol       Date:  2011-12-02       Impact factor: 53.106

Review 4.  Emerging antibody combinations in oncology.

Authors:  Stephen J Demarest; Kandasamy Hariharan; Jianying Dong
Journal:  MAbs       Date:  2011-07-01       Impact factor: 5.857

Review 5.  Therapeutic cancer vaccines.

Authors:  Cornelis J M Melief; Thorbald van Hall; Ramon Arens; Ferry Ossendorp; Sjoerd H van der Burg
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

6.  Agonist antibodies to TNFR molecules that costimulate T and NK cells.

Authors:  Ignacio Melero; Daniel Hirschhorn-Cymerman; Aizea Morales-Kastresana; Miguel F Sanmamed; Jedd D Wolchok
Journal:  Clin Cancer Res       Date:  2013-03-01       Impact factor: 12.531

7.  Putting the brakes on BTLA in T cell-mediated cancer immunotherapy.

Authors:  Chrystal M Paulos; Carl H June
Journal:  J Clin Invest       Date:  2009-12-28       Impact factor: 14.808

8.  SimB16: modeling induced immune system response against B16-melanoma.

Authors:  Francesco Pappalardo; Ivan Martinez Forero; Marzio Pennisi; Asis Palazon; Ignacio Melero; Santo Motta
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

9.  A mathematical model of immune-system-melanoma competition.

Authors:  Marzio Pennisi
Journal:  Comput Math Methods Med       Date:  2012-06-03       Impact factor: 2.238

10.  Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells.

Authors:  Alfonso R Sánchez-Paulete; Francisco J Cueto; María Martínez-López; Sara Labiano; Aizea Morales-Kastresana; María E Rodríguez-Ruiz; Maria Jure-Kunkel; Arantza Azpilikueta; M Angela Aznar; José I Quetglas; David Sancho; Ignacio Melero
Journal:  Cancer Discov       Date:  2015-10-22       Impact factor: 39.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.